A study of thymidylate synthase expression as a biomarker for resectable colon cancer: Alliance (cancer and Leukemia group B) 9581 and 89803

Oncologist

Volumn 22, Issue 1, 2017, Pages 107-114

  Niedzwiecki, Donna ^a   Hasson, Rian M ^b   Lenz, Heinz Josef ^c   Ye, Cynthia ^a   Redston, Mark ^b   Ogino, Shuji ^b,d   Fuchs, Charles S ^d   Compton, Carolyn C ^e   Mayer, Robert J ^d   Goldberg, Richard M ^f   Colacchio, Thomas A ^g   Saltz, Leonard B ^h   Warren, Robert S ⁱ   Bertagnolli, Monica M ^b  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d DANA FARBER CANCER INSTITUTE   (United States)

^e ARIZONA STATE UNIVERSITY   (United States)

^f OHIO STATE UNIVERSITY   (United States)

^g DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^h MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Adjuvant therapy; Biomarkers; Colon cancer; Microsatellite instability; Mismatch repair deficiency; Thymidylate synthase

Indexed keywords

B RAF KINASE; EDRECOLOMAB; FLUOROURACIL; THYMIDYLATE SYNTHASE; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER PROGNOSIS; CANCER SURGERY; CANCER SURVIVAL; COLON CANCER; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DNA SYNTHESIS; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LEUKEMIA; MAJOR CLINICAL STUDY; MALE; MISMATCH REPAIR; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; SCORING SYSTEM; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; CANCER STAGING; COLON TUMOR; GENE EXPRESSION REGULATION; GENETICS; MICROSATELLITE INSTABILITY; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PROGNOSIS; TREATMENT OUTCOME;

AGED; BIOMARKERS, TUMOR; COLONIC NEOPLASMS; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICROSATELLITE INSTABILITY; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; THYMIDYLATE SYNTHASE; TREATMENT OUTCOME;

EID: 85011333645     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2016-0215     Document Type: Article

References (26)

1. Chung KY, Saltz LB. Adjuvant therapy of colon cancer: Current status and future directions. Cancer J 2007;13:192-197.
2. Moertel CG, Fleming TR, Macdonald JS et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 1990;322: 352-358.
3. Moertel CG, Fleming TR, Macdonald JS et al. Intergroup study of fluorouracil plus levamisole as adjuvant therapy for stage II/Dukes’ B2 colon cancer. J Clin Oncol 1995;13:2936-2943.
4. Ladner RD. The role of dUTPase and uracil-DNA repair in cancer chemotherapy. Curr Protein Pept Sci 2001;2:361-370.
5. Thibodeau SN, Bren G, Schaid D. Microsatellite instability in cancer of the proximal colon. Science 1993;260:816-819.
6. Bertagnolli MM, Redston M, Compton CC et al. Microsatellite instability and loss of heterozygosity at chromosomal location 18q: Prospective evaluation of biomarkers for stages II and III colon cancer-a study of CALGB 9581 and 89803. J Clin Oncol 2011; 29:3153-3162.
7. Samowitz WS, Curtin K, Ma KN et al. Microsatellite instability in sporadic colon cancer is associated with an improved prognosis at the population level. Cancer Epidemiol Biomarkers Prev 2001;10:917-923.
8. Watanabe T, Wu TT, Catalano PJ et al. Molecular predictors of survival after adjuvant chemotherapy for colon cancer. N Engl J Med 2001;344:1196-1206.
9. Ogino S, Shima K, Meyerhardt JA et al. Predictive and prognostic roles of BRAF mutation in stage III colon cancer: Results from intergroup trial CALGB 89803. Clin Cancer Res 2012;18:890-900.
10. Saltz LB, Niedzwiecki D, Hollis D et al. Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: Results of CALGB 89803. J Clin Oncol 2007;25:3456-3461.
11. Niedzwiecki D, Bertagnolli MM, Warren RS et al. Documenting the natural history of patients with resected stage II adenocarcinoma of the colon after random assignment to adjuvant treatment with edrecolomab or observation: Results from CALGB 9581. J Clin Oncol 2011;29:3146-3152.
12. Sinicrope FA, Rego RL, Halling KC et al. Thymidylate synthase expression in colon carcinomas with microsatellite instability. Clin Cancer Res 2006;12:2738-2744.
13. Popat S, Chen Z, Zhao D et al. A prospective, blinded analysis of thymidylate synthase and p53 expression as prognostic markers in the adjuvant treatment ofcolorectal cancer. Ann Oncol 2006;17: 1810-1817.
14. Johnston PG, Fisher ER, Rockette HE et al. The role of thymidylate synthase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer. J Clin Oncol 1994;12:2640-2647.
15. Bertagnolli MM, Niedzwiecki D, Compton CC et al. Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: Cancer and Leukemia Group B Protocol 89803. J Clin Oncol 2009;27:1814-1821.
16. Gonen M, Hummer A, Zervoudakis A et al. Thymidylate synthase expression in hepatic tumors is a predictorofsurvival and progression in patients with resectable metastatic colorectal cancer. J Clin Oncol 2003;21:406-412.
17. Lenz H-J, Danenberg KD, Leichman CG et al. p53 and thymidylate synthase expression in untreated stage II colon cancer: Associations with recurrence, survival, and site. Clin Cancer Res 1998; 4:1227-1234.
18. Johnston PG, Lenz HJ, Leichman CG et al. Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res 1995;55:1407-1412.
19. Popat S, Matakidou A, Houlston RS. Thymidylate synthase expression and prognosis in colorectal cancer: Asystematic review and meta-analysis. J Clin Oncol 2004;22:529-536.
20. Allegra CJ, Paik S, Colangelo LH et al. Prognostic value of thymidylate synthase, Ki-67, and p53 in patients with Dukes’ B and C colon cancer: A National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project collaborative study. J Clin Oncol 2003;21:241-250.
21. Edler D, Glimelius B, Hallstrom M et al. Thymidylate synthase expression in colorectal cancer: A prognostic and predictive marker of benefit from adjuvant fluorouracil-based chemotherapy. J Clin Oncol 2002;20:1721-1728.
22. Roth AD, Teipar S, Delorenzi M et al. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: Results of the translational study on the PETACC-3, EORTC 40993, SAKK60-00 trial. J Clin Oncol 2010;28:466-474.
23. Gavin PG, Colangelo LH, Fumagalli D et al. Mutation profiling and microsatellite instability in stage II and III colon cancer: An assessment oftheir prognostic and oxaliplatin predictive value. Clin Cancer Res 2012;18:6531-6541.
24. Ribic CM, Sargent DJ, Moore MJ et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 2003;349:247-257.
25. Sargent DJ, Marsoni S, Monges G et al. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapyin colon cancer. J Clin Oncol 2010;28:3219-3226.
26. Sargent DJ et al. Confirmation of deficient mismatch repair (dMMR) as a predictive marker for lack of benefit from 5-FU based chemotherapy in stage II and III colon cancer(CC): Apooled molecular reanalysis of randomized chemotherapy trials. ASCO Meeting Abstr 2008;26(suppl 15):4008.